Physician profile
Richard K Mark
NPI 1003918905
$1,461.28
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,437 · 2022: $24.41.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $133.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $125.30 | 2019 | |
| Janssen Biotech, INC. | $120.26 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.48 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $106.73 | 2019 | |
| Novo Nordisk INC | $83.48 | 2019 | |
| Pfizer INC. | $73.80 | 2019 | |
| Supernus Pharmaceuticals, INC. | $70.47 | 2019 | |
| Merck Sharp & Dohme LLC | $66.74 | 2019 | |
| Amarin Pharma, INC. | $64.80 | 2019 | |
| Glaxosmithkline, LLC. | $59.24 | 2019 | |
| Celgene Corporation | $57.85 | 2019 | |
| Mayne Pharma Commercial LLC | $57.08 | 2019 | |
| Lilly USA, LLC | $53.24 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $51.50 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.27 | 2019 | |
| Shire North American Group INC | $32.09 | 2019 | |
| Bioventus LLC | $21.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.36 | 2019 | |
| Vivus LLC | $19.45 | 2019 | |
| Amgen INC. | $19.05 | 2019 | |
| Sanofi Pasteur INC. | $18.53 | 2019 | |
| Allergan, INC. | $14.43 | 2019 | |
| Journey Medical Corporation | $13.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.70 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Mark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.